123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism
Identifieur interne : 008012 ( Main/Merge ); précédent : 008011; suivant : 008013123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism
Auteurs : Schwarz [Allemagne] ; Klaus Tatsch [Allemagne] ; Thomas Gasser [Allemagne] ; Guy Arnold [Allemagne] ; Oliver Pogarell [Allemagne] ; Gais Künig [Allemagne] ; Wolfgang H. Oertel [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-01.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Apomorphine, Apomorphine (diagnostic use), Basal Ganglia Diseases (drug therapy), Basal Ganglia Diseases (metabolism), Benzamides (diagnostic use), Benzamides (metabolism), Chi-Square Distribution, Disease Progression, Dopamine Agonists (therapeutic use), Follow-Up Studies, Humans, IBZM‐SPECT, Iodine Radioisotopes (diagnostic use), Iodine Radioisotopes (metabolism), Levodopa, Levodopa (therapeutic use), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson's disease, Prognosis, Prospective Studies, Severity of Illness Index, Tomography, Emission-Computed, Single-Photon, Treatment Outcome.
- MESH :
- chemical , diagnostic use : Apomorphine, Benzamides, Iodine Radioisotopes.
- drug therapy : Basal Ganglia Diseases, Parkinson Disease.
- metabolism : Basal Ganglia Diseases, Benzamides, Iodine Radioisotopes, Parkinson Disease.
- chemical , therapeutic use : Dopamine Agonists, Levodopa.
- Adult, Aged, Aged, 80 and over, Chi-Square Distribution, Disease Progression, Follow-Up Studies, Humans, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Tomography, Emission-Computed, Single-Photon, Treatment Outcome.
Abstract
We performed a prospective clinical follow up (mean follow up, 36 months; range, 24–56 months) of 65 patients with de novo parkinsonism in whom imaging of dopamine D2 receptors was performed before the initiation of dopaminomimetic therapy by means of 123I‐iodobenzamidesingle‐photon‐emission computed tomography (IBZM‐SPECT). The results of IBZM‐SPECT were comared with the long‐term response to dopaminomimetic drugs, the development of motor fluctuations, and the development of clinical signs incompatible with Parkinson's disease (PD). A total of 55 patients had normal and 10 patients had reduced IBZM binding; 45 patients showed a good response to levodopa (L‐dopa), 11 showed an equivocal response, and nine did not respond; 31 patients developed a fluctuating response to dopaminomimetic drugs and seven patients developed clinical signs indicative of multiple‐system atrophy (n = 5), progressive supranuclear palsy (n = 1), or corticobasal ganglionic degeneration (n = 1). Chi‐squared analysis showed a significant correlation of the results of IBZM‐SPECT with the long‐term response to dopaminomimetic therapy (p < 0.0001) and the development of motor fluctuations (p < 0.0001) or clinical signs incompatible with PD (p < 0.0001). We conclude that IBZM‐SPECT can help to differentiate between patients who will show a good response to L‐dopa and will develop motor fluctuations (most likely patients with PD) and those patients who will not respond to L‐dopa and might develop clinical signs compatible with another hypokinetic disorder of the basal ganglia.
Url:
DOI: 10.1002/mds.870130107
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002898
- to stream Istex, to step Curation: 002898
- to stream Istex, to step Checkpoint: 003835
- to stream PubMed, to step Corpus: 004523
- to stream PubMed, to step Curation: 004523
- to stream PubMed, to step Checkpoint: 004524
- to stream Ncbi, to step Merge: 004E62
- to stream Ncbi, to step Curation: 004E62
- to stream Ncbi, to step Checkpoint: 004E62
Links to Exploration step
ISTEX:C82F777A0E968DC0CE551B41DF878389F9ED786FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism</title>
<author><name sortKey="Schwarz" sort="Schwarz" uniqKey="Schwarz" last="Schwarz">Schwarz</name>
</author>
<author><name sortKey="Tatsch, Klaus" sort="Tatsch, Klaus" uniqKey="Tatsch K" first="Klaus" last="Tatsch">Klaus Tatsch</name>
</author>
<author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
</author>
<author><name sortKey="Arnold, Guy" sort="Arnold, Guy" uniqKey="Arnold G" first="Guy" last="Arnold">Guy Arnold</name>
</author>
<author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
</author>
<author><name sortKey="Kunig, Gais" sort="Kunig, Gais" uniqKey="Kunig G" first="Gais" last="Künig">Gais Künig</name>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C82F777A0E968DC0CE551B41DF878389F9ED786F</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130107</idno>
<idno type="url">https://api.istex.fr/document/C82F777A0E968DC0CE551B41DF878389F9ED786F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002898</idno>
<idno type="wicri:Area/Istex/Curation">002898</idno>
<idno type="wicri:Area/Istex/Checkpoint">003835</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Schwarz:i:ibzm:binding</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:9452320</idno>
<idno type="wicri:Area/PubMed/Corpus">004523</idno>
<idno type="wicri:Area/PubMed/Curation">004523</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004524</idno>
<idno type="wicri:Area/Ncbi/Merge">004E62</idno>
<idno type="wicri:Area/Ncbi/Curation">004E62</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004E62</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Schwarz J:i:ibzm:binding</idno>
<idno type="wicri:Area/Main/Merge">008012</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism</title>
<author><name sortKey="Schwarz" sort="Schwarz" uniqKey="Schwarz" last="Schwarz">Schwarz</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Current Address: Department of Neurology, University of Ulm, D‐89081 Ulm</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author><name sortKey="Tatsch, Klaus" sort="Tatsch, Klaus" uniqKey="Tatsch K" first="Klaus" last="Tatsch">Klaus Tatsch</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Nuclear Medicine, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Arnold, Guy" sort="Arnold, Guy" uniqKey="Arnold G" first="Guy" last="Arnold">Guy Arnold</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kunig, Gais" sort="Kunig, Gais" uniqKey="Kunig G" first="Gais" last="Künig">Gais Künig</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Current Address: Department of Neurology, Philipps University, D‐35033 Marburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Giessen</region>
<settlement type="city">Marbourg</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-01">1998-01</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="16">16</biblScope>
<biblScope unit="page" to="19">19</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C82F777A0E968DC0CE551B41DF878389F9ED786F</idno>
<idno type="DOI">10.1002/mds.870130107</idno>
<idno type="ArticleID">MDS870130107</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Apomorphine</term>
<term>Apomorphine (diagnostic use)</term>
<term>Basal Ganglia Diseases (drug therapy)</term>
<term>Basal Ganglia Diseases (metabolism)</term>
<term>Benzamides (diagnostic use)</term>
<term>Benzamides (metabolism)</term>
<term>Chi-Square Distribution</term>
<term>Disease Progression</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>IBZM‐SPECT</term>
<term>Iodine Radioisotopes (diagnostic use)</term>
<term>Iodine Radioisotopes (metabolism)</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson's disease</term>
<term>Prognosis</term>
<term>Prospective Studies</term>
<term>Severity of Illness Index</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Apomorphine</term>
<term>Benzamides</term>
<term>Iodine Radioisotopes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Basal Ganglia Diseases</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia Diseases</term>
<term>Benzamides</term>
<term>Iodine Radioisotopes</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Chi-Square Distribution</term>
<term>Disease Progression</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Prognosis</term>
<term>Prospective Studies</term>
<term>Severity of Illness Index</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a prospective clinical follow up (mean follow up, 36 months; range, 24–56 months) of 65 patients with de novo parkinsonism in whom imaging of dopamine D2 receptors was performed before the initiation of dopaminomimetic therapy by means of 123I‐iodobenzamidesingle‐photon‐emission computed tomography (IBZM‐SPECT). The results of IBZM‐SPECT were comared with the long‐term response to dopaminomimetic drugs, the development of motor fluctuations, and the development of clinical signs incompatible with Parkinson's disease (PD). A total of 55 patients had normal and 10 patients had reduced IBZM binding; 45 patients showed a good response to levodopa (L‐dopa), 11 showed an equivocal response, and nine did not respond; 31 patients developed a fluctuating response to dopaminomimetic drugs and seven patients developed clinical signs indicative of multiple‐system atrophy (n = 5), progressive supranuclear palsy (n = 1), or corticobasal ganglionic degeneration (n = 1). Chi‐squared analysis showed a significant correlation of the results of IBZM‐SPECT with the long‐term response to dopaminomimetic therapy (p < 0.0001) and the development of motor fluctuations (p < 0.0001) or clinical signs incompatible with PD (p < 0.0001). We conclude that IBZM‐SPECT can help to differentiate between patients who will show a good response to L‐dopa and will develop motor fluctuations (most likely patients with PD) and those patients who will not respond to L‐dopa and might develop clinical signs compatible with another hypokinetic disorder of the basal ganglia.</div>
</front>
</TEI>
<double doi="10.1002/mds.870130107"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism</title>
<author><name sortKey="Schwarz" sort="Schwarz" uniqKey="Schwarz" last="Schwarz">Schwarz</name>
</author>
<author><name sortKey="Tatsch, Klaus" sort="Tatsch, Klaus" uniqKey="Tatsch K" first="Klaus" last="Tatsch">Klaus Tatsch</name>
</author>
<author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
</author>
<author><name sortKey="Arnold, Guy" sort="Arnold, Guy" uniqKey="Arnold G" first="Guy" last="Arnold">Guy Arnold</name>
</author>
<author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
</author>
<author><name sortKey="Kunig, Gais" sort="Kunig, Gais" uniqKey="Kunig G" first="Gais" last="Künig">Gais Künig</name>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C82F777A0E968DC0CE551B41DF878389F9ED786F</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130107</idno>
<idno type="url">https://api.istex.fr/document/C82F777A0E968DC0CE551B41DF878389F9ED786F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002898</idno>
<idno type="wicri:Area/Istex/Curation">002898</idno>
<idno type="wicri:Area/Istex/Checkpoint">003835</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Schwarz:i:ibzm:binding</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism</title>
<author><name sortKey="Schwarz" sort="Schwarz" uniqKey="Schwarz" last="Schwarz">Schwarz</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Current Address: Department of Neurology, University of Ulm, D‐89081 Ulm</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author><name sortKey="Tatsch, Klaus" sort="Tatsch, Klaus" uniqKey="Tatsch K" first="Klaus" last="Tatsch">Klaus Tatsch</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Nuclear Medicine, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Arnold, Guy" sort="Arnold, Guy" uniqKey="Arnold G" first="Guy" last="Arnold">Guy Arnold</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kunig, Gais" sort="Kunig, Gais" uniqKey="Kunig G" first="Gais" last="Künig">Gais Künig</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwing‐Maximilians University, and “Parkinson's Disease and Other Basal Ganglia Disorders” BMFT Research Program, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Current Address: Department of Neurology, Philipps University, D‐35033 Marburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Giessen</region>
<settlement type="city">Marbourg</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-01">1998-01</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="16">16</biblScope>
<biblScope unit="page" to="19">19</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C82F777A0E968DC0CE551B41DF878389F9ED786F</idno>
<idno type="DOI">10.1002/mds.870130107</idno>
<idno type="ArticleID">MDS870130107</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apomorphine</term>
<term>IBZM‐SPECT</term>
<term>Levodopa</term>
<term>Parkinson's disease</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a prospective clinical follow up (mean follow up, 36 months; range, 24–56 months) of 65 patients with de novo parkinsonism in whom imaging of dopamine D2 receptors was performed before the initiation of dopaminomimetic therapy by means of 123I‐iodobenzamidesingle‐photon‐emission computed tomography (IBZM‐SPECT). The results of IBZM‐SPECT were comared with the long‐term response to dopaminomimetic drugs, the development of motor fluctuations, and the development of clinical signs incompatible with Parkinson's disease (PD). A total of 55 patients had normal and 10 patients had reduced IBZM binding; 45 patients showed a good response to levodopa (L‐dopa), 11 showed an equivocal response, and nine did not respond; 31 patients developed a fluctuating response to dopaminomimetic drugs and seven patients developed clinical signs indicative of multiple‐system atrophy (n = 5), progressive supranuclear palsy (n = 1), or corticobasal ganglionic degeneration (n = 1). Chi‐squared analysis showed a significant correlation of the results of IBZM‐SPECT with the long‐term response to dopaminomimetic therapy (p < 0.0001) and the development of motor fluctuations (p < 0.0001) or clinical signs incompatible with PD (p < 0.0001). We conclude that IBZM‐SPECT can help to differentiate between patients who will show a good response to L‐dopa and will develop motor fluctuations (most likely patients with PD) and those patients who will not respond to L‐dopa and might develop clinical signs compatible with another hypokinetic disorder of the basal ganglia.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.</title>
<author><name sortKey="Schwarz, J" sort="Schwarz, J" uniqKey="Schwarz J" first="J" last="Schwarz">J. Schwarz</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Tatsch, K" sort="Tatsch, K" uniqKey="Tatsch K" first="K" last="Tatsch">K. Tatsch</name>
</author>
<author><name sortKey="Gasser, T" sort="Gasser, T" uniqKey="Gasser T" first="T" last="Gasser">T. Gasser</name>
</author>
<author><name sortKey="Arnold, G" sort="Arnold, G" uniqKey="Arnold G" first="G" last="Arnold">G. Arnold</name>
</author>
<author><name sortKey="Pogarell, O" sort="Pogarell, O" uniqKey="Pogarell O" first="O" last="Pogarell">O. Pogarell</name>
</author>
<author><name sortKey="Kunig, G" sort="Kunig, G" uniqKey="Kunig G" first="G" last="Künig">G. Künig</name>
</author>
<author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9452320</idno>
<idno type="pmid">9452320</idno>
<idno type="doi">10.1002/mds.870130107</idno>
<idno type="wicri:Area/PubMed/Corpus">004523</idno>
<idno type="wicri:Area/PubMed/Curation">004523</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004524</idno>
<idno type="wicri:Area/Ncbi/Merge">004E62</idno>
<idno type="wicri:Area/Ncbi/Curation">004E62</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004E62</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Schwarz J:i:ibzm:binding</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.</title>
<author><name sortKey="Schwarz, J" sort="Schwarz, J" uniqKey="Schwarz J" first="J" last="Schwarz">J. Schwarz</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Tatsch, K" sort="Tatsch, K" uniqKey="Tatsch K" first="K" last="Tatsch">K. Tatsch</name>
</author>
<author><name sortKey="Gasser, T" sort="Gasser, T" uniqKey="Gasser T" first="T" last="Gasser">T. Gasser</name>
</author>
<author><name sortKey="Arnold, G" sort="Arnold, G" uniqKey="Arnold G" first="G" last="Arnold">G. Arnold</name>
</author>
<author><name sortKey="Pogarell, O" sort="Pogarell, O" uniqKey="Pogarell O" first="O" last="Pogarell">O. Pogarell</name>
</author>
<author><name sortKey="Kunig, G" sort="Kunig, G" uniqKey="Kunig G" first="G" last="Künig">G. Künig</name>
</author>
<author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Apomorphine (diagnostic use)</term>
<term>Basal Ganglia Diseases (drug therapy)</term>
<term>Basal Ganglia Diseases (metabolism)</term>
<term>Benzamides (diagnostic use)</term>
<term>Benzamides (metabolism)</term>
<term>Chi-Square Distribution</term>
<term>Disease Progression</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Iodine Radioisotopes (diagnostic use)</term>
<term>Iodine Radioisotopes (metabolism)</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Prognosis</term>
<term>Prospective Studies</term>
<term>Severity of Illness Index</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Apomorphine</term>
<term>Benzamides</term>
<term>Iodine Radioisotopes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Basal Ganglia Diseases</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia Diseases</term>
<term>Benzamides</term>
<term>Iodine Radioisotopes</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Chi-Square Distribution</term>
<term>Disease Progression</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Prognosis</term>
<term>Prospective Studies</term>
<term>Severity of Illness Index</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a prospective clinical follow up (mean follow up, 36 months; range, 24-56 months) of 65 patients with de novo parkinsonism in whom imaging of dopamine D2 receptors was performed before the initiation of dopaminomimetic therapy by means of 123I-iodobenzamide-single-photon-emission computed tomography (IBZM-SPECT). The results of IBZM-SPECT were compared with the long-term response to dopaminomimetic drugs, the development of motor fluctuations, and the development of clinical signs incompatible with Parkinson's disease (PD). A total of 55 patients had normal and 10 patients had reduced IBZM binding; 45 patients showed a good response to levodopa (L-dopa), 11 showed an equivocal response, and nine did not respond; 31 patients developed a fluctuating response to dopaminomimetic drugs and seven patients developed clinical signs indicative of multiple-system atrophy (n = 5), progressive supranuclear palsy (n = 1), or corticobasal ganglionic degeneration (n = 1). Chi-squared analysis showed a significant correlation of the results of IBZM-SPECT with the long-term response to dopaminomimetic therapy (p < 0.0001) and the development of motor fluctuations (p < 0.001) or clinical signs incompatible with PD (p < 0.0001). We conclude that IBZM-SPECT can help to differentiate between patients who will show a good response to L-dopa and will develop motor fluctuations (most likely patients with PD) and those patients who will not respond to L-dopa and might develop clinical signs compatible with another hypokinetic disorder of the basal ganglia.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008012 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 008012 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:C82F777A0E968DC0CE551B41DF878389F9ED786F |texte= 123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism }}
This area was generated with Dilib version V0.6.23. |